FDA approves licence extension of golimumab to include paediatric use for active psoriatic arthritis

FDA has approved golimumab for treatment of patients 2 years of age and older with psoriatic arthritis. Currently in UK, golimumab is only licensed for treatment of active and progressive psoriatic arthritis in adult patients.

Source:

Biospace Inc.